The latest biotech news

News and Trends 9 Jun 2023

Astellas developing new gastric cancer drug

Astellas Pharma Inc. has submitted a new drug application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab. Zolbetuximab is a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, […]

June 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Jun 2023

Quell in potential $2B AstraZeneca cell therapy deal

Quell Therapeutics Ltd, a developer of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications. “We are extremely pleased to have AstraZeneca on […]

June 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 8 Jun 2023

Acepodia raises $100M financing to boost cell therapies

Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its antibody-cell conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, has announced a $100 million Series D financing. The funds will be used to progress the company’s pipeline of enhanced cell therapies for solid tumors and hematologic […]

June 8, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 8 Jun 2023

Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

Gene therapy company Kate Therapeutics Inc. (KateTx), has emerged from stealth mode with a $51 million Series A financing. In addition, the company has granted Astellas Pharma Inc. an exclusive, worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM). There are a large number of genetically defined and complex muscle […]

June 8, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 8 Jun 2023

Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients

Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked adrenoleukodystrophy (X-ALD) patients with cerebral adrenoleukodystrophy (cALD). X-ALD is an orphan neurodegenerative disease. The global incidence of X-ALD is approximately six to eight per 100,000 live births. […]

June 8, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 7 Jun 2023

AAVantgarde closes €61M financing to move gene delivery program to the clinic

AAVantgarde Bio, a clinical-stage, Italian-based international biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery, has closed a €61 million ($65.1 million) Series A financing. The amount represents the largest series A round ever in Italian biotech. AAVantgarde has two proprietary, AAV-based large gene delivery platforms: one leveraging DNA recombination, […]

June 7, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jun 2023

Head and neck cancer data presented at ASCO 2023

Results from promising trials in the fight against head and neck cancer have been presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a provider of IT, network and AI technologies, announced new […]

June 6, 2023 - 7 minutesmins - By Jim Cornall

News and Trends 6 Jun 2023

Shasqi using click chemistry to target cancer

Shasqi, Inc., whose mission is to revolutionize cancer treatment with click chemistry, has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc. Through the collaboration, Shasqi will apply its tumor-targeted Click Activated Protodrugs Against Cancer (CAPAC) platform to the development of new cancer therapies. Shasqi’s CAPAC platform relies on chemistry, not biology, […]

June 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Jun 2023

Rabies vaccine gets phase 3 trial approval

YS Biopharma Co. Ltd.’s PIKA rabies vaccine has been granted phase 3 clinical trial approval from the Food and Drug Administration of the Philippines. The phase 3 clinical trial, which is planned to commence later in 2023, is a multi-center, multi-country study designed to evaluate the safety and immunogenicity of the vaccine. The study will […]

June 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Jun 2023

Bacterial resistance genes a ‘threat to human health’

Genes that make bacteria resistant to antibiotics are much more widespread in our environment than was previously realized. A new study, from Chalmers University of Technology and the University of Gothenburg in Sweden, shows that bacteria in almost all environments carry resistance genes, with a risk of them spreading and aggravating the problem of bacterial […]

June 5, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 2 Jun 2023

Faux filet: World’s first 3D-printed ready-to-cook fish produced

As biotechs come up with fascinating, new ways to cultivate food, Israel-based Steakholder Foods has created the first-ever 3D-printed fish filets. These ready-to-cook filets, which are developed from animal cells that are grown in laboratories, are obtained from the startup’s proprietary 3D bioprinters and customized bio-inks. Said to have the same taste and texture as […]

June 2, 2023 - 3 minutesmins - By Roohi Mariam Peter

News and Trends 2 Jun 2023

Scientists develop probe to push for new drug discoveries

A study by Loughborough University and the University of Oxford in the U.K. has led to the development of a small molecule probe that could deepen the understanding of a crucial cellular messenger and lead to the development of new therapeutic drugs. The research paper showcases the researchers’ innovative probe that binds to inositol pyrophosphate […]

June 2, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Astellas developing new gastric cancer drug

Quell in potential $2B AstraZeneca cell therapy deal

Acepodia raises $100M financing to boost cell therapies

Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients

AAVantgarde closes €61M financing to move gene delivery program to the clinic

Head and neck cancer data presented at ASCO 2023

Shasqi using click chemistry to target cancer

Rabies vaccine gets phase 3 trial approval

Bacterial resistance genes a ‘threat to human health’

Faux filet: World’s first 3D-printed ready-to-cook fish produced

Scientists develop probe to push for new drug discoveries

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!